In Brief: Genzyme Sepracoat
This article was originally published in The Gray Sheet
Executive Summary
Genzyme Sepracoat: Bioresorbable anti-adhesion solution receives European Union CE mark for use in abdominal, pelvic, and thoracic surgical procedures, the firm announces Aug. 19. Genzyme plans a forth quarter launch of the device in Denmark, Germany, Italy, The Netherlands, Sweden, and the United Kingdom. A PMA for Sepracoat, submitted in January ("The Gray Sheet" Jan. 29, In Brief), is under expedited review at FDA...